Introduction
For people with end-stage organ failure, organ transplantation is a critical treatment that often becomes their only choice. However, there are risks involved, some of which have been since the beginning. Cancer is one of the three main reasons for death after organ transplantation, and it is a serious issue. The other two are cardiovascular disease and infection. Post-transplant malignancy persists as a challenge even if the incidence of cardiovascular disease and infections is declining as a result of better screening, preventive measures, and therapeutic approaches.
The lack of set criteria and poor knowledge about early identification are the main reasons for the inadequate knowledge regarding post-transplant cancers. Changes in immune dynamics, host response, and a variety of clinical manifestations are some of the variables that raise the risk of cancer following organ transplantation. Research shows a significant two to four-fold increased risk of cancer following organ transplantation. This increased risk highlights the need for more investigation to fully understand the complex interactions among variables that lead to post-transplant cancers. For transplant recipients to have better results, it is essential to develop screening protocols and recommendations for early diagnosis.
What Are the Key Factors and Implications of Organ Transplant and Cancer Risk?
According to a recent study, organ transplant recipients are more likely to develop 32 distinct cancer forms. Among these, non-Hodgkin lymphoma (which accounted for 14 percent of all cancers in this group), lung cancer (13 percent), liver cancer (nine percent), and kidney cancer (seven percent) were the most common cancers among transplant patients.
Depending on the kind of transplant received, there were different risks of cancer development. For example, the highest risk of lung cancer was among recipients of lung transplants. As a result of pre-existing lung conditions, which raise the risk, lung transplants are frequently performed. However, after a lung transplant, cancer usually spreads to the remaining sick lung rather than the new lung. The risk of liver cancer was much higher in recipients of liver transplants, possibly due to the incidence of diabetes in transplant recipients or infections with hepatitis B or C in the transplanted liver. However, for all kinds of transplant recipients, the risk of kidney cancer increased.
While transplants are an essential treatment for patients with end-stage organ disorders, they also put recipients at higher risk of malignancy. The drugs used to suppress the immune system and prevent organ rejection are partially to blame for this elevated risk. Due to immunosuppression, the cancer risk in transplant recipients is similar to that of HIV-positive people; both have increased risks for malignancies connected to infection.
What Is the Etiology of Cancer Caused in Transplant Recipients?
-
Risk Factors Associated With Patients - Numerous factors might increase one's risk of developing skin cancer, such as increasing age, sun exposure, having a family history of cancer, and engaging in specific lifestyle choices like drinking alcohol or smoking. Alcohol consumption and smoking greatly increase the risk of cancer and death. The development of cancer is facilitated by viruses such as the Epstein-Barr virus (EBV), hepatitis B and C, the human papillomavirus (HPV), human herpesvirus 8 (HHV-8), and Merkel cell polyomavirus. For example, EBV is associated with nasopharyngeal malignancies, leiomyosarcoma, post-transplant lymphoproliferative disorder (PTLD), Hodgkin disease, and non-Hodgkin lymphoma. All of these factors work together to affect the risk of cancer following transplantation.
-
Transplant-Related Risk Factors - The risk of malignancy is correlated with the kind of transplant. PTLD and genitourinary malignancy are less common in patients who receive kidneys from living donors. Although rare, donor transmission has been linked to the development of post-transplant malignancies; cases of glioblastoma multiforme, melanoma, lung, breast, colon, rectum, and kidney cancer, as well as Kaposi sarcoma, have all been known to be transmissible from donors.
-
Risk Factors Associated With Medication - Immunosuppressive medications make it more difficult for the body to detect and fight abnormal cells, which increases the risk of cancer caused by viruses. The type, potency, and duration of these medications all affect the risk of developing cancer. Numerous immunosuppressive medications have been connected to this elevated risk of cancer, including antimetabolites (like Azathioprine and Mycophenolate mofetil), biologics (like Basiliximab, Anti-thymocyte globulin), corticosteroids, mTOR inhibitors (like Rapamycin, Everolimus), and calcineurin inhibitors (like Tacrolimus, Cyclosporine).
How Is Cancer in Transplant Recipients Treated and Managed?
Detecting an underlying pre-existing malignancy through careful screening of the patient and donor before transplantation is one of the most efficient strategies to prevent the development of cancer in the later stages of transplantation.
-
Reduction of Immunosuppression: Patients who have received a kidney transplant benefit most from reducing or stopping immunosuppressive therapy because renal transplant recipients do not usually die from the loss of their graft due to rejection. Certain treatments, like PTLD, some skin malignancies, and Kaposi sarcoma (KS), may occasionally produce tumor regression. It might be significant to reduce exposure to calcineurin inhibitors.
-
Anogenital Malignancies: Topical Fluorouracil, electrocautery, and laser therapy treat in situ anogenital cancers. Wide local excision (for example, APR) combined with inguinal lymphadenectomy is necessary for invasive cancers.
-
Visceral Malignancy: Standard surgery, radiotherapy, or chemotherapy techniques treat visceral cancers.
-
Post-transplant Lymphoproliferative Disorder (PTLD): The principal options for the treatment include immunosuppression reduction, chemotherapy, radiation therapy, immunotherapy using the CD20 monoclonal antibody (Rituximab), or a combination of these.
What Is the Prognosis of Cancer in Transplant Recipients?
Following transplantation, malignant neoplasms exhibit distinct clinical characteristics that contribute to increased mortality. According to the Israel Penn International Transplant Tumor Registry, individuals who received a solid organ transplant had a poorer stage-specific survival rate for cancer of the bladder, prostate, colon, lung, and breast than those who did not. Recipients with colorectal, prostate, and non-small-cell lung cancer have a lower percentage survival rate than the general population who have the same type of cancer.
Conclusion
Recipients of solid organs should get counseling and instruction on how to keep a lookout for cancer occurrences. It is recommended that patients receive counseling regarding risk factors that can be modified, such as immunosuppressive medications and untreated viral infections, as there is a period of opportunity to prevent malignancies after transplantation. To ensure that patients receive a successful organ transplant and have a high quality of life, the entire healthcare team must collaborate to offer bedside care, education, physical and psychological support, and ongoing follow-up exams. Clinics and hospitals should make cancer screening and surveillance part of their standard operating procedures for healthcare plans. As part of the protocol in the posttransplant period, all team members should be informed about dermatological inspections, sun protection programs, and self-screening tools for all patients. Encouraging all patients to receive screening tools and education during the postoperative phase guarantees that they will retain the knowledge that the physician has imparted.
